Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 7Venous Thromboembolism 3Venous Thrombosis 2Thrombosis 2Thromboembolism 2Pulmonary Embolism 2Prostatic Neoplasms 2Urinary Tract Infections 1Unspecified Adult Solid Tumor, Protocol Specific 1Staphylococcal Infections 1Spasm 1Sleep Initiation and Maintenance Disorders 1Sepsis 1Seizures 1Schizophrenia, Treatment-Resistant 1Schizophrenia 1Sarcoma, Alveolar Soft Part 1Retinitis 1Renal Insufficiency, Chronic 1Pulmonary Arterial Hypertension 1Prostate Cancer Patients 1Pneumonia 1Pharmacokinetics of MDV3100 1Pancreatic Neoplasms 1Pain 1Ovarian Neoplasms 1Neutropenia 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Multiple Myeloma 1

Interventions

Warfarin 1Dalteparin 14-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Embolism and Thrombosis × Warfarin × Clear all
NCT00216866 2017-08-28

The Catheter Study: Central Venous Catheter Survival in Cancer Patients Using Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombosis

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Phase 2 Completed
70 enrolled

Embolism, Thrombosis, Embolism and Thrombosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡